Activity Overview
This online, on-demand virtual symposium brings together renowned experts in hematologic malignancies. In this educational program, these experts discuss long-term survivorship among patients who have undergone CAR T-cell therapy. In particular, they describe how they manage prolonged complications and those that manifest long after delivery of treatment, with an emphasis on principles for early recognition and management. Concepts like disease surveillance and supportive care are also emphasized in this presentation.
This educational activity is an archive of the live symposium held on July 21, 2026.
Target Audience
This educational activity is directed toward medical oncologists, hematologist-oncologists, hematologists, advanced practice providers, nurses, and other health care practitioners involved in the management of hematologic malignancies.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate prevention strategies and multidisciplinary care approaches to optimize safety and outcomes in patients receiving CAR-T therapy
- Devise multidisciplinary approaches to address key challenges related to integrating CAR-T therapies in the community
Jesús G. Berdeja, MD
Director, Multiple Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, TN
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Bristol Myers Squibb, Galapagos, Janssen, Johnson & Johnson, Karyopharm, Kite Pharma, Kyowa Kirin, Pfizer, Regeneron, Roche, Whitehawk Therapeutics; Grant/Research Funding: AstraZeneca, Bristol Myers Squibb, C4 Therapeutics, Caribou Biosciences, GSK, Genentech, Gracell, Ichnos Sciences, Johnson & Johnson, Juno Therapeutics, K36 Therapeutics, Karyopharm, Kite Pharma, Pfizer, Roche, Sanofi
Nicholas Barkemeyer, PA-C, MPAS
Physician Assistant
Tennessee Oncology
Nashville, TN
Disclosures: Speakers Bureau: Johnson & Johnson
Michael Byrne, DO, FACP
Director of Cellular Therapy Research
Greco-Hainsworth Centers for Research
Director, Cellular Therapy Program
Tennessee Oncology
Medical Director for Cellular Therapy
OneOncology
Nashville, TN
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Concert Pharmaceuticals (DSMC)
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
